Blood pressure medicines protect less when doses are missed

Researchers next examined whether those pressure differences translated into protection from major cardiovascular events. They counted:

• strokes;
• heart attacks, also called myocardial infarction;
• ischemic heart disease, meaning reduced blood flow to the heart muscle; and
• heart failure that led to hospitalization or death.

For participants with higher adherence, the treatment group had an 11% lower incidence of major cardiovascular events than the comparator group. For the lower-adherence group, the analysis found no statistically significant reduction—that is, no reduction it could confidently distinguish from chance.

“Notably, our results reinforce the saying that ‘drugs don’t work in patients who don’t take them.’ Patients with lower adherence derived little or no cardiovascular benefit, whereas those with higher adherence had greater reductions in blood pressure and prevention of cardiovascular events,” Yang said.

However, the absence of a statistically significant reduction does not prove that lower-adherence patients received exactly zero benefit. The result instead shows that the event benefit became less certain as medication-taking became less consistent.

Takeaway: Taking enough medicine determined whether the treatment produced a clear blood-pressure and cardiovascular benefit.

Why does this matter for hypertension care?

An estimated 1.4 billion adults worldwide between the ages of 30 and 79 have high blood pressure, a major contributor to illness and death. Although medicines that lower blood pressure have proven cardiovascular benefits, approximately half of patients do not take their prescriptions as directed.

The findings point to a straightforward treatment chain: more consistent dosing accompanied larger systolic-pressure differences, and those larger differences accompanied fewer major cardiovascular events. The measured protection tracked sustained medicine use rather than the receipt of a prescription alone.

The pooled analysis cannot establish what any single missed dose does on its own. These were conference findings, and the available account did not provide confidence intervals—ranges expressing uncertainty around each estimate—or a detailed account of how adherence was measured. It also did not break the results down by individual medicine.

Because the trials used either placebo or less intensive regimens as comparators, the 11% represents a pooled result across different treatment contexts. It should not be read as a guaranteed benefit for every patient or regimen.

Takeaway: The 11% figure is a strong signal from the pooled trials, not a universal or certain outcome for an individual patient.

What can clinicians and patients do?

The researchers recommend making consistent medication use a greater priority in hypertension care. Their proposed measures include:

• assessing medication adherence routinely;
• providing clearer patient education and practical ways to follow treatment;
• simplifying medication schedules and, where appropriate, combining multiple treatments into one pill; and
• considering longer-acting medicines that may limit the consequences of an occasional missed dose.

“For years, we have neglected non-adherence to medication as a cause for uncontrolled hypertension,” said Professor Felix Mahfoud, chair of the European Society of Cardiology's Communication Committee. “Assessment of adherence should become a routine part of hypertension care so patients do not miss out on life-saving benefits.”

Mahfoud also called for open, non-judgmental conversations between healthcare providers and patients about any barriers they face in taking medicine. For clinicians, this moves medication-taking from an assumed point of compliance to a measurable part of hypertension treatment.

Takeaway: Hypertension care gains much of its protective value only when patients can take the prescribed medicine consistently.